InhalPlus Receives €2.8 Million in Non-Dilutive Funding

This week we received both official grant notifications: €2.8 million in non-dilutive funding is now secured.

We are proud and grateful to have secured two separate grants, from EXIST (€1.5 million, starting December 2024) and from the Institute for Biomedical Translation (IBT Lower Saxony) (€1.3 million, starting April 2025). Each grant supports a distinct phase of our project, and the funding does not overlap.

EXIST: With support from EXIST, we will refine our current prototype at Fraunhofer ITEM and work closely with nursing staff and neonatologists to improve usability. In parallel, we will prepare the regulatory documentation and processes for the clinical investigation required on the way to CE marking.

IBT: The IBT Lower Saxony grant funds a clinical proof-of-concept study with our clinical partners. It will investigate whether the efficiency advantage we have shown in the laboratory carries over to clinical practice.

This funding is more than financial support. It is a strong vote of confidence in our goal of improving neonatal care. We will keep you posted as we build evidence, refine our technology and work towards a lasting difference for preterm infants worldwide.